CSV April 4, 2023 through April 4, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NUCLEIC	APPENDICES	*USP43–NF38*	7865	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Appendix 2*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ACID-BASED TECHNIQUES -- GENERAL								Delete the Row for dNTP dinucleotide triphosphate
RALTEGRAVIR TABLETS	DEFINITION	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	Change ($C_{20}H_{20}FN_6O_5$) to: ($C_{20}H_{21}FN_6O_5$)
RALTEGRAVIR CHEWABLE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	3835	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
ALOSETRON HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	141	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability*/*Suitability requirements*/ *Resolution*: Change NLT 7 to: NLT 3

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CALCIUM AND VITAMIN D WITH MINERALS TABLETS	STRENGTH	*USP43–NF38*	4845	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Calcium, Copper, Magnesium, Manganese, and Zinc, Method 2/Acceptance criteria*: Change NLT 90.0%–125.0% to: 90.0%–125.0%
DAPSONE TABLETS	IDENTIFICATION/*B.*	*USP43–NF38*	1241	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Ultraviolet Absorption* <197U> to: *Spectroscopic Identification Tests* <197>, *Ultraviolet-Visible Spectroscopy*: 197U
WATER-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP43–NF38*	5512	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Biotin, Method 3/Solid-phase extraction*: Change anion-xchange to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								anion-exchange AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis*: Delete

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								, calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4*/*Analysis*: Add ascorbic acid ($C_6H_8O_6$),
EPINEPHRINE	IMPURITIES/ *Enantiomeric Purity*	*USP43–NF38*	Online	24-Apr-2020	1-May-2020	*NA*	*NA*	This erratum applies to the USP-NF ONLINE platform only. In *System suitability*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Change 0.03 mg/mL of in *Mobile phase* to: 0.03 mg/mL of USP Racepinephrine Hydrochloride RS in *Mobile phase*
POLYOXYL 35 CASTOR OIL	IDENTIFICATION/*C. Identity by Fatty Acid Composition*	*USP43–NF38*	5956	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability/Suitability requirements/Relative standard deviation*: Change linoeate to: linoleate
MENADIONE	ASSAY/*Procedure*	*USP43–NF38*	2780	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Endpoint detection*: Change Potentiometric to: Visual
IDENTIFICATION TESTS—GENERAL	CHEMICAL IDENTIFICATION TESTS	*USP43–NF38*	6587	24-Apr-2020	1-Aug-2020	*NA*	*NA*	In *Bicarbonate/B.*: Change (1:20) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(1 in 20) AND In *Borate*/*A.*: Change (1:50): to: (1 in 50): AND In *Calcium*/*A.*: Change (1:20) to: (1 in 20) AND In *Carbonate*/*B.*: Change (1:20) to: (1 in 20) AND In *Chloride*/*B.*: Change (1:100), to: (1 in 100), AND In *Cobalt*/*A.*: Change (1:20) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PROPOFOL	IM PUR ITIES/*Organic Impurities, Procedure 2*	*USP43–NF38*	3739	24-Apr-2020	1-May-2020	*NA*	*NA*	(1 in 20) AND Change (1:10) to: (1 in 10) AND In *Tartrate/A.*: Change (1:20). to: (1 in 20). In *Table 3*: Delete Propofol related compound B[b] 0.8 1.0 0.05 AND Change Propofol related compound A[c] to: Propofol related compound A[b] AND Change [b] 2,6-Diisopropylbenzoquinone. [c] 3,3?-5,5?-Tetrai

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sopropyldiphenol. to: [b] 3,3?-5,5?-Tetraisopropyldiphenol.
RALTEGRAVIR TABLETS	IMPURITIES/*Organic Impurities*	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
VITAMIN A TABLETS	ASSAY/ *Procedure 2*	*USP43–NF38*	4635	24-Apr-2020	1-May-2020	*NA*	*NA*	In the variable definition list in *Analysis*: Change *Sample solution 1* to: *Sample solution*
ITRACONAZOLE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 1*	*Revision Bulletin (Official August 01, 2019)*	Online	27-Mar-2020	1-Apr-2020	*NA*	*NA*	In *System suitability/Suitability require*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ments/*Relative standard deviation*: Change NMT 2.0% for 5 replicate injections to: NMT 2.0% for 5 replicates
ANTITHROMBIN III HUMAN	SPECIFIC TESTS	*USP42–NF37*	350	27-Mar-2020	1-Apr-2020	*NA*	*NA*	In *Pyrogen Test <151>*: Change USP Antithrombin III Units to: Antithrombin III IU
ANTITHROMBIN III HUMAN	ADDITIONAL REQUIREMENTS	*USP42–NF37*	350	27-Mar-2020	1-Apr-2020	*NA*	*NA*	In *Labeling*: Change USP Antithrombin III Units. to: Antithrombin III IU.
CALCIUM ACETATE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official January 01, 2020)*	Online	28-Feb-2020	1-Mar-2020	*NA*	*NA*	In *Test 1*/*Analysis*: Change dissolved at time point (*i*):

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Result$_i$ = (r_U/r_S) × C_S × V × D × (1/L) × 100 to: dissolved: Result = (r_U/r_S) × C_S × V × D × (1/L) × 100 AND In *Test 3*/*Analytical procedure 1*/*Analysis*: Change V = volume of *Medium*, 900 mL to: V = volume of *Medium 1*, 900 mL AND In *Test 3*/*Analytical procedure 2*/*Analysis*: Change V_M = volume of *Medium*, 900 mL to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								V_M = volume of *Medium 1*, 900 mL AND In *Test 3*/*Analytical procedure 3*/*Blank*: Change *Medium* to: *Medium 2* AND In *Test 3*/*Analytical procedure 3*/*Analysis*: Change V_M = volume of *Medium*, 900 mL to: V_M = volume of *Medium 2*, 900 mL
FLUNIXIN MEGLUMINE INJECTION	IMPURITIES/*Organic Impurities*	*USP42–NF37*	1890	28-Feb-2020	1-Mar-2020	*NA*	*NA*	In *Sensitivity solution*: Change in *Diluent* from the *Standard solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: in *Diluent*
LITHIUM CARBONATE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 1*	*USP42–NF37*	2598	28-Feb-2020	1-Mar-2020	*NA*	*NA*	In *Analysis*: Change *V* = volume of *Medium*, 900 mL to: *V* = volume of *Medium*, 800 mL
DICLOXACILLIN SODIUM CAPSULES	PERFORMANCE TESTS	*USP42–NF37*	1330	28-Feb-2020	1-Mar-2020	*NA*	*NA*	In *Dissolution <711>*: Change *Sample solution*: Sample per the chapter. Dilute with *Medium* to a concentration that is similar to the *Standard solution*. *Tolerances*: NLT 75% (*Q*) of the labeled amount of dicloxacillin ($C_{19}H_{17}Cl_2N_3O_5S$) is dissolved. to: *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Sample per the chapter. Pass a portion of the solution under test through a suitable filter. Dilute with *Medium* to a concentration that is similar to the *Standard solution*. *Instrumental conditions* Mode: UV-Vis *Tolerances*: NLT 75% (*Q*) of the labeled amount of dicloxacillin ($C_{19}H_{17}Cl_2N_3O_5S$) is dissolved.
ALFADEX	CHEMICAL INFORMATION	*USP42–NF37*	5561	31-Jan-2020	1-Feb-2020	*NA*	*NA*	Change 972.84 to: 972.85
MEROPENEM FOR INJECTION	ASSAY/ *Procedure*	*Second Supplement to USP42–NF37*	9216	31-Jan-2020	1-Feb-2020	*NA*	*NA*	In *Mobile phase*: Change *Solution A* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POLYETHYLENE GLYCOL	CHEMICAL INFORMATION	*USP42–NF37*	5882	31-Jan-2020	1-Feb-2020	*NA*	*NA*	*Buffer* See https://www.usp nf.com/sites/default/files/usp_pdf/EN/january-2020-errata-with-image.pdf for correction
CYPROHEPTADINE HYDROCHLORIDE ORAL SOLUTION	IMPURITIES/*Organic Impurities*	*USP42–NF37*	1195	27-Dec-2019	1-Jan-2020	*NA*	*NA*	In *Standard solution*: Change in *Solution B* to: in *Diluent*
INSULIN ASSAYS	ASSAY/*Rabbit Blood Sugar Method—Quantitative*	*Revision Bulletin (Official May 01, 2019)*	Online	27-Dec-2019	1-Jan-2020	*NA*	*NA*	In *Standard stock solution*: Change of USP Insulin RS of the appropriate species to: of the USP Insulin Reference Standard of the appropriate species AND In *Sample stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Change of USP Insulin RS of the appropriate species. to: of the USP Insulin Reference Standard of the appropriate species.
CUPRIC CHLORIDE	REAGENTS AND REFERENCE TABLES/*Reagent Specifications*	*USP42–NF37*	6092	27-Dec-2019	1-Jan-2020	*NA*	*NA*	Change [7447-39-4]. to: [10125-13-0].
ULTRAVIOLET-VISIBLE SPECTROSCOPY	QUALIFICATION OF UV-VIS SPECTROMETERS	*Second Supplement to USP42–NF37*	9570	27-Dec-2019	1-Jan-2020	*NA*	*NA*	In all instances in *Table 4*: Change < to: ? AND In *Control of Photometric Response/Acidic Nicotinic Acid*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Solutions in 0.1 N Hydrochloric Acid/paragraph 1: Change Using nicotinic acid solutions, the absorbance accuracy must be ± 0.01 $A_?$. to: Using nicotinic acid solutions, the absorbance accuracy must be ± 0.010 $A_?$ (for values below 1.00 $A_?$).
SIMVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	4009	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Standard solution*: Change USP Simvastatin RS in *Medium* to: USP Simvastatin RS in *Medium*. Transfer a portion of the solution to a centrifuge tube

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								containing about 10 mg of *Prewashed manganese dioxide* per milliliter of transferred solution under test, and mix. Allow the mixture to stand for 30 min with occasional shaking, centrifuge, and use a portion of the clear supernatant.
VALIDATION OF MICROBIAL RECOVERY FROM PHARMACOPEIAL ARTICLES	VALIDATION OF NEUTRALIZATION METHODS—RECOVERY COMPARISONS	*Second Supplement to USP42–NF37*	9616	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In paragraph 1 in *Recovery on Agar Medium*: Change If it is necessary to solubilize the test stample, to: If it is necessary to solubilize the test sample,
MEFENAMIC ACID	PERFORMANCE	*USP42–NF37*	2711	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change *Solution A*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES	TESTS/ *Dissolution <711>*							*Mobile phase*, *Standard solution*, *Sample solution*, *Chromatographic system*, and *System suitability*: Proceed as directed in the *Assay*, making any necessary volumetric adjustments. to: *Solution A*, *Mobile phase*, *Standard solution*, *Chromatographic system*, and *System suitability*: Proceed as directed in the *Assay*, making any necessary volumetric adjustments. *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution: Take a portion of the solution under test, and dilute if necessary.
0.1 N POTASSIUM HYDROXIDE VS	REAGENTS AND REFERENCE TABLES/*Solutions*	*USP42–NF37*	6185	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change *Standardization*: Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N potassium hydroxide VS. Titrate with 0.1 N hydrochloric acid VS until a permanent pale-pink color is produced. to: *Standardization*: Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N hydrochloric acid VS. Titrate with the potassium hydroxide solution until a permanent pale-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								pink color is produced.
ROPINIROLE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official July 01, 2019)*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Test 2* and *Test 3* in *Analysis*: Change $Result_1 = C_1 \times (1/L) \times (M_{r1}/M_{r2}) \times 100$ to: $Result_1 = C_1 \times V \times (1/L) \times (M_{r1}/M_{r2}) \times 100$
ZIPRASIDONE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 3/Tier 2*	*Revision Bulletin (Official October 01, 2019)*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Buffer*: Change 6.8 g/L g to: 6.8 g/L AND In *Standard stock solution 2*: Change *Standard stock solution* to: *Standard stock solution 1*
ANALYTICAL METHODOLOGIES BASED ON SCATTERING	1. OVERVIEW: GENERAL CHAPTERS BASED ON	*Second Supplement to USP42–NF37*	9634	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In Row 6 of Column 4 in *Table 1*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PHENOMENA—GENERAL	SCATTERING PHENOMENA							Also properties of condensated phrases to: Also properties of condensated phases
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS	IMPURITIES/*Organic Impurities*	*Second Supplement to USP42–NF37*	9101	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Table 4, Footnote h*: Change 0.47, to: 0.45,
25% TETRABUTYLAMMONIUM HYDROXIDE TS	REAGENTS AND REFERENCE TABLES/*Solutions*	*Second Supplement to USP42–NF37*	9336	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change Transfer about 34.82 g to: Transfer about 77.1 g
SODIUM BICARBONATE	IMPURITIES/*Carbonate/Analysis*	*USP42–NF37*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Remove the external reference to a reagent in Sodium Bicarbonate
2,5-DIHYDROXYBENZOIC ACID	REAGENTS AND REFERENCE TABLES/*Reagent Specifications*	*USP42–NF37*	6097	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change [303-07-1]. to: [490-79-9].

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—SMALL ANGLE X-RAY SCATTERING AND SMALL ANGLE NEUTRON SCATTERING	6. EXPERIMENTAL CONSIDERATIONS	*Second Supplement to USP42–NF37*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *6.2 Resolution*/*6.2.1 Size resolution*: Change $q_{min} < ?/d_{max}$?/d_{max} to: $q_{min} < ?/d_{max}$
DEPYROGENATION BY RINSING	ROUTINE PROCESS CONTROL	*USP42–NF37*	8067	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In the first paragraph: Change WFI to: Water for Injection
BIOLOGICAL INDICATORS—RESISTANCE PERFORMANCE TESTS	D-VALUE DETERMINATION	*USP42–NF37*	6385	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In the third paragraph in *Procedure*: Change stated spore filter to: stated spore titer
GADOTERIDOL	*Limit of gadoteridol related*	*USP42–NF37*	2020	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In *Chromatographic system*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	compound A							Change packing L21 to: packing L47
STEAM STERILIZATION OF AQUEOUS LIQUIDS	BIOBURDEN/BIOLOGICAL INDICATOR METHOD/*Routine Process Control*	*USP42–NF37*	8082	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In the first paragraph: Change calibrartion to: calibration
TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE	INTRODUCTION	*USP42–NF37*	8021	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In paragraphs 4 and 5: Change a probability of a PNSU to: a PNSU
HYPROMELLOSE ACETATE SUCCINATE	ASSAY	*USP42–NF37*	5772	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In *Content of Methoxy and 2-Hydroxypropoxy Groups/ Analysis*: Change Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_{r1}/M_{r2}) \times 100$ AND Change Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$
MICROBIOLOGICAL PROCEDURES FOR ABSENCE OF SPECIFIED MICROORGANISMS—NUTRITIONAL AND DIETARY SUPPLEMENTS	BUFFER AND MEDIA/*Media*	*USP42–NF37*	8514	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In Row 5 of Column 2 for L-Cystine in *Fluid Selenite–Cystine Medium*: Change 10.0 g to: 10.0 mg
AMIODARONE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP42–NF37*	253	27-Sep-2019	1-Oct-2019	*NA*	*NA*	See https://www.usp nf.com/sites/def ault/files/usp_pd f/EN/september -2019-errata- with-image.pdf for correction.
DESFLURANE	ADDITIONAL REQUIREMENTS/*USP*	*USP42–NF37*	1230	27-Sep-2019	1-Oct-2019	*NA*	*NA*	In USP Desflurane Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Reference Standards <11>							Compound A RS: Change Bis-(1,2,2,2-tetrafluoroethyl)ether. to: Bis-(1,2,2,2-tetrafluoroethyl)ether; Also known as: 1,1,1,2-Tetrafluoro-2-(1,2,2,2-tetrafluoroethoxy)ethane.
BENZALDEHYDE	ASSAY/ *Procedure*	*USP42–NF37*	5586	27-Sep-2019	1-Oct-2019	*NA*	*NA*	In *Chromatographic system*: Delete *Detector temperature*: 25°

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 10
- Page 11
- Page 12
- Page 13